circadian clock comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
=== Genes are commonly interrupted by introns that must be removed by RNA splicing === Analysis of mature eukaryotic messenger RNA molecules showed that they are often much smaller than the DNA sequences that encode them. The genes were shown to be discontinuous, composed of sequences that are not present in the final mature RNA (introns), located between sequences that are retained in the mature RNA (exons). Introns were shown to be removed after transcription through a process termed RNA splicing. Splicing of RNA transcripts requires a highly precise and coordinated sequence of molecular events, consisting of (a) definition of boundaries between exons and introns, (b) RNA strand cleavage at exactly those sites, and (c) covalent linking (ligation) of the RNA exons in the correct order. The discovery of discontinuous genes and RNA splicing was entirely unexpected by the community of RNA biologists, and stands as one of the most shocking findings in molecular biology research.
=== Branding === In 1996, while renovating the first Raising Cane’s location near LSU, Graves uncovered an old mural from a former bakery, "Wolf's Bakery", that inspired the restaurant's logo with its red-brick tones, flowing white script, and a yellow tagline declaring "bread at its best". The name "Raising Cane's" pays tribute to his yellow Labrador, Cane. Locations feature custom murals. These brand elements can be seen in official merchandise released by Raising Cane's. In addition, Raising Cane's sells limited-edition merchandise, like the Graduation Plush Puppy released in 2025. They held a fashion show in 2025 at New York Fashion Week, designed by Joe Ando-Hirsh.
The flowers are small, produced on pendulous spikes 4 to 8 cm (1+1⁄2 to 3 in) long at the leaf nodes, the spikes lengthening up to 7 to 15 cm (2+3⁄4 to 6 in) as the fruit matures. A single stem bears 20 to 30 fruiting spikes. The fruit of the black pepper is a drupe and when dried is known as a peppercorn.Within the genus Piper, black pepper is most closely related to other Asian species such as P. caninum.
On 30 August 2023, Health Secretary Steve Barclay announced that it would be upgraded to a statutory inquiry, enabling witnesses to be compelled to give evidence. The inquiry, chaired by Lady Justice Thirlwall, formally opened on 22 November 2023. The public hearings began on 10 September 2024. In a ruling on 29 May 2024, the chair determined that remote live viewing would be available to Core Participants, their legal representatives and the media, but not to the wider public. During the hearings, colleagues gave evidence describing Letby as "excited and gossipy" when discussing the death of an infant, saying she preferred caring for unwell babies, complained when moved to less acute areas, and expressed eagerness for the first death of an infant to "get it out of the way". Former Health Secretary Jeremy Hunt apologised to families during the 2025 hearings, saying the government had taken "too long" to act. Letby's lawyers and other supporters later asked for the inquiry to be paused while her application to the Criminal Cases Review Commission was considered. Thirlwall rejected the request in March 2025 and said she intended to deliver her report in November 2025. In April 2026, the inquiry said that work on the report was still ongoing and that a publication date could not be confirmed.
=== Judges' Costumes === Episode 1: Carla Hall as a bloody victim, Zac Young as Chucky, Stephanie Boswell as the final girl Episode 2: Carla Hall and Stephanie Boswell as terrifying twins (inspired by the Grady Twins from The Shining), Zac Young as an archaeologist (inspired by Indiana Jones) Episode 3: Carla Hall as an evil cheerleader, Zac Young as a vampire glam rock star, Stephanie Boswell as Mistress of the Dark (inspired by Elvira) Episode 4: Carla Hall as an undead fitness instructor, Zac Young as a voodoo doll, Stephanie Boswell as goblin king (inspired by Jareth from the 1986 movie Labyrinth) Episode 5: Carla Hall as dancing queen who only made it to seventeen, Zac Young as tuxedo wolfman, Stephanie Boswell as bloody prom queen (inspired by Carrie White) Episode 6: Carla Hall as deadly disco queen, Zac Young as vicious poodle, Stephanie Boswell as creepy clown Episode 7: Carla Hall as cat lady, Zac Young as devilish boss, Stephanie Boswell as Dollface
Sources: en.wikipedia.org
Elizabeth Evans Hughes Gossett (August 19, 1907 – April 21, 1981), the daughter of statesman Charles Evans Hughes, was the first American, and one of the first people in the world, treated with insulin for type 1 diabetes. She received over 42,000 insulin shots over her lifetime.
Diabetes Research Center Einstein-Rockefeller-CUNY Center for AIDS Research Harold and Muriel Block Institute for Clinical and Translational Research at Einstein and Montefiore Institute for Aging Research Montefiore Einstein Comprehensive Cancer Center New York Regional Center for Diabetes Translation Research Rose F. Kennedy Intellectual and Developmental Disabilities Research Center
Hypotension not due to arrhythmia Bradycardia Accelerated idioventricular rhythm Elderly Ehlers–Danlos syndromes; efficiency of local anesthetics can be reduced Pseudocholinesterase deficiency Intra-articular infusion (this is not an approved indication and can cause chondrolysis) Porphyria, especially acute intermittent porphyria; lidocaine has been classified as porphyrogenic because of the hepatic enzymes it induces, although clinical evidence suggests it is not. Bupivacaine is a safe alternative in this case. Impaired liver function – people with lowered hepatic function may have an adverse reaction with repeated administration of lidocaine because the drug is metabolized by the liver. Adverse reactions may include neurological symptoms (e.g. dizziness, nausea, muscle twitches, vomiting, or seizures).
The longest Romanian word is pneumonoultramicroscopicsilicovolcaniconioză, with 44 letters, (meaning "pneumonultramicroscopicsilicovolcanoconiosis") but the longest one admitted by the Dicționarul explicativ al limbii române ("Explanatory Dictionary of the Romanian Language", DEX) is electroglotospectrografie, with 25 letters.
Sources: en.wikipedia.org
== In vitro == Theanine is structurally similar to the excitatory neurotransmitter glutamate and binds to glutamate receptors in vitro, though with much lower affinity in comparison. Specifically, it binds to ionotropic glutamate receptors in the micromolar range, including the AMPA and kainate receptors and, to a lesser extent, the NMDA receptor. It acts as an antagonist of the former two sites, and a partial co-agonist of the NMDA receptors. In vitro, theanine also binds to group I mGluRs. In addition, it inhibits glutamine transporters and glutamate transporters, and thus blocks the reuptake of glutamine and glutamate. Theanine may elicit umami taste, a consequence potentially associated with binding to and activation of the T1R1 + T1R3 heterodimer or umami (savory) taste receptor.
=== IDMS standardization effort === One problem with any creatinine-based equation for GFR is that the methods used to assay creatinine in the blood differ widely in their susceptibility to non-specific chromogens, which cause the creatinine value to be overestimated. In particular, the MDRD equation was derived using serum creatinine measurements that had this problem. The NKDEP program in the United States has attempted to solve this problem by trying to get all laboratories to calibrate their measures of creatinine to a "gold standard", which in this case is isotope dilution mass spectrometry (IDMS). In late 2009 not all labs in the U.S. had changed over to the new system. There are two forms of the MDRD equation that are available, depending on whether or not creatinine was measured by an IDMS-calibrated assay. The CKD-EPI equation is designed to be used with IDMS-calibrated serum creatinine values only.
=== Orphaned === In November 2023, one month into the war, aid workers began using the term WCNSF (“Wounded Child No Surviving Family”) to describe children who had been injured and lost all family members. In late-August 2024, an estimated 19,000 children had lost one or both of their parents. UNICEF reported that extended families were taking on the responsibility of caring for orphaned children. Many orphaned children described the pain of being unable to properly say goodbye to their parents and siblings, due to lack of funeral or memorial services, uncertainty of the future and delay at being told due to medical fragility. Older siblings and extended family also took on responsibility for caring for their younger siblings after being orphaned. In early February 2024, UNICEF estimated that at least 17,000 children had been orphaned. Some children were left without even extended family remaining. In the Middle East, adoption by non-relatives is uncommon, as extended families traditionally assume responsibility for orphaned children. However, UNICEF reports that families already struggling to feed and shelter their own children are often unable or unwilling to take in additional dependents. By October 2024, the estimated number of orphans in Gaza had grown to 20,000. In early September 2025, 2,596 children had lost both parents, according to UNICEF, citing figures from Gaza's health ministry. Furthermore, 53,724 children had lost one parent, 47,804 their father and 5,920 their mother.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.